Hepatitis B: Clinical Trials

40 trials for Hepatitis B, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

40 terminated. 40 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 240Terminated 40
Phase 14Terminated 4
Phase 31Terminated 1

Follow Hepatitis B: new trials by email Literature Review of Hepatitis B trials Research Report on Hepatitis B

Trials (filtered) newest first · largest first

All 40 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV
Selgantolimod, Placebo - Hepatitis B, HIV Infections
Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)292023-05-012026-11-17
Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
STSG-0002 Injection - Chronic Hepatitis b
Phase 2TerminatedStaidson (Beijing) Biopharmaceuticals Co., Ltd92023-04-252023-12-19
To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B
STSG-0002 Injection - Chronic Hepatitis b
Phase 2TerminatedStaidson (Beijing) Biopharmaceuticals Co., Ltd92023-04-252023-12-19
Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins
Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®) - Chronic Hepatitis B
Phase 2TerminatedHannover Medical School132022-08-152025-09-04
Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
GSK3965193, Placebo to match GSK3965193, Bepirovirsen - Hepatitis B
Phase 1 / Phase 2TerminatedGlaxoSmithKline742022-04-142026-10-14
A Study of Safety and Efficacy of ATI-2173 and Vebicorvir in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection
ATI-2173 25mg, Vebicorvir 300mg, Viread 300Mg Tablet - Chronic Hepatitis b
Phase 2TerminatedAntios Therapeutics, Inc22022-04-112022-05-31
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil - Hepatitis B, Chronic
Phase 2TerminatedJanssen Research & Development, LLC12021-11-032024-03-06
A Study to Evaluate the Antiviral Activity and Safety of HH-003 Injection in Subjects With Chronic Hepatitis B and Hepatitis D Co-infection
HH-003 20mg/kg, HH-003 3mg/kg - Chronic Hepatitis B and Hepatitis D Co-infection
Phase 2TerminatedHuahui Health92021-08-112023-10-10
A Study Evaluating Treatment Regimens Containing Vebicorvir (ABI-H0731) in Participants With Chronic Hepatitis B Infection
VBR, AB-729, SOC NrtI - Chronic Hepatitis B
Phase 2TerminatedAssembly Biosciences652021-05-072023-11-14
A Study of Safety and Efficacy of ATI-2173 in Combination With Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B Virus Infection and in Subjects With Hepatitis D Virus Coinfection
ATI-2173, Viread, AB-729 - Hepatitis B, Chronic, Hepatitis D
Phase 2TerminatedAntios Therapeutics, Inc402021-03-302022-11-18
A Study Evaluating ABI-H0731-containing Regimens in Chinese Participants With Chronic Hepatitis B Virus Infection
ABI-H0731, ETV, Peg-IFNα - Chronic Hepatitis B
Phase 2TerminatedAssembly Biosciences542021-02-182023-10-06
HepTcell Immunotherapy in Patients With Inactive Chronic Hepatitis B (CHB)
HepTcell, Placebo - Hepatitis B, Chronic
Phase 2TerminatedAltimmune, Inc.872020-12-262025-12-08
A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
ABI-H0731, Placebo, NrtI - Chronic Hepatitis B
Phase 2TerminatedAssembly Biosciences22020-11-112022-10-20
Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study
HEC121120 tablets, HEC121120 placebo tablets, entecavir tablets - Hepatitis B, Chronic
Phase 1 / Phase 2TerminatedSunshine Lake Pharma Co., Ltd.522020-10-092024-06-24
A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection
ABI-H2158, Placebo, Entecavir (ETV) - Chronic Hepatitis B
Phase 2TerminatedAssembly Biosciences882020-08-282022-09-15
Study of EYP001a to Assess Its Safety and Anti-viral Effect in CHB Patients in Combination With NA (ETV or TD)
EYP001a, Placebo, Nucleotide analogue (Entecavir or Tenofovir Disoproxil) - Hepatitis B, Chronic
Phase 2TerminatedEnyo Pharma262020-05-122022-11-02
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
Inarigivir soproxil, Tenofovir alafenamide fumarate (TAF) - Hepatitis B, HBV
Phase 2TerminatedF-star Therapeutics, Inc.52019-10-102020-07-21
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic, Hepatitis B e Antigen-negative Subjects Infected With HBV Virus and Receiving or Stopping Treatment With a NUC Inhibitor
Inarigivir soproxil, Nucleoside/nucleotide (NUC) analogue inhibitors - Hepatitis B, HBV
Phase 2TerminatedF-star Therapeutics, Inc.642019-06-182020-07-22
Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients
inarigivir soproxil - HBV, Hepatitis B
Phase 2TerminatedF-star Therapeutics, Inc.82019-04-112020-04-29
A Study Evaluating the Utility of Ambrisentan in Lowering Portal Pressure in Patients With Liver Cirrhosis
Ambrisentan - Cirrhosis, Portal Hypertension
Phase 2TerminatedNoorik Biopharmaceuticals AG192019-04-112021-02-26

Showing 20 of 40. Sign in to see all of them.

Narrower conditions

Hepatitis B, Chronic (26)  ·  Hepatitis (2)  ·  Hepatitis C (2)  ·  Hepatitis D (2)  ·  Ascites (1)  ·  Bronchiolitis Obliterans Syndrome (1)  ·  Carcinoma (1)  ·  Carcinoma, Hepatocellular (1)  ·  Diphtheria (1)  ·  Esophageal and Gastric Varices (1)  ·  Fibrosis (1)  ·  HIV Infections (1)  ·  Haemophilus Infections (1)  ·  Hypertension, Portal (1)

Broader conditions

Blood-Borne Infections (40)  ·  Communicable Diseases (40)  ·  DNA Virus Infections (40)  ·  Digestive System Diseases (40)  ·  Hepadnaviridae Infections (40)  ·  Hepatitis, Viral, Human (40)  ·  Infections (40)  ·  Liver Diseases (40)  ·  Virus Diseases (40)  ·  Hepatitis (38)  ·  Pathologic Processes (28)  ·  Pathological Conditions, Signs and Symptoms (28)  ·  Disease Attributes (27)  ·  Chronic Disease (26)  ·  Hepatitis, Chronic (26)

Interventions

Tenofovir (12)  ·  entecavir (12)  ·  ARC-520 (6)  ·  Histamine Antagonists (4)  ·  tenofovir alafenamide (4)  ·  clevudine (3)  ·  hepatitis B hyperimmune globulin (2)  ·  peginterferon alfa-2a (2)  ·  Chlorpheniramine (1)  ·  Diphenhydramine (1)  ·  Dosage Forms (1)  ·  Emtricitabine (1)  ·  Hepatitis B Vaccines (1)  ·  Nucleobindins (1)  ·  Nucleosides (1)

Sponsors

Arrowhead Pharmaceuticals (6)  ·  Assembly Biosciences (5)  ·  Bukwang Pharmaceutical (3)  ·  F-star Therapeutics, Inc. (3)  ·  GlaxoSmithKline (3)  ·  Antios Therapeutics, Inc (2)  ·  Staidson (Beijing) Biopharmaceuticals Co., Ltd (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Altimmune, Inc. (1)  ·  Bausch Health Americas, Inc. (1)  ·  Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1)  ·  Dynavax Technologies Corporation (1)  ·  Eisai Limited (1)  ·  Enyo Pharma (1)  ·  Gilead Sciences (1)

Countries

China (12)  ·  South Korea (11)  ·  United States (10)  ·  Canada (9)  ·  Hong Kong (9)  ·  Germany (7)  ·  United Kingdom (7)  ·  New Zealand (6)  ·  Spain (5)  ·  Taiwan (5)  ·  Thailand (5)  ·  Australia (4)  ·  Poland (4)  ·  France (3)  ·  Moldova (3)

Top investigators

Hyo Suk Lee, M.D., Ph.D. (3)  ·  Don Mitchell (2)  ·  Guiqiang Wang (2)  ·  Bruce Given, MD (1)

Results publications

PMID 16628625, PMID 24995515, PMID 33712437, PMID 34029994, PMID 38510983

NIH funding

2014 (3), 2015 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)